Page last updated: 2024-08-17

quinoxalines and Substance Withdrawal Syndrome

quinoxalines has been researched along with Substance Withdrawal Syndrome in 67 studies

Research

Studies (67)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (10.45)	18.2507
2000's	21 (31.34)	29.6817
2010's	38 (56.72)	24.3611
2020's	1 (1.49)	2.80

Authors

Authors	Studies
Chang, CT; Choo, SJ; Harun, SN; Latif, MFA; Sanusi, NA; Tangiisuran, B	1
Bekker, A; Kang, S; Li, J; Ye, JH	1
Bekker, A; Chen, X; Fan, Q; Fu, R; Li, J; Mei, Q; Shiwalkar, N; Ye, JH; Zuo, W	1
Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW	1
Blendy, JA; Carlson, GC; Gould, TJ; Poole, RL; Turner, JR; Wilkinson, DS	1
Berg, A; Foulds, J; Franzon, M; Galaznik, A; Hughes, JR; Russ, C; Yu, CR; Zou, KH	1
Dhanji, AR; Hajek, P; McRobbie, H; Smith, KM	1
Alexander, JC; Bruijnzeel, AW; Igari, M; Ji, Y; Papke, RL; Qi, X	1
Hays, JT	1
Blendy, JA; DeDominicis, KE; Forcelli, PA; Hussmann, GP; Kellar, KJ; Klehm, J; Lindstrom, J; Richardson, JR; Sahibzada, N; Turner, JR; Wolfe, BB; Xiao, Y; Yasuda, RP	1
Aitken, D; Clyde, M; Corran, B; Els, C; Pipe, A; Reid, RD; Tulloch, H	1
Cicero Guerrero, A; Cristóbal Fernández, M; Jiménez-Ruiz, CA; Mayayo Ulibarri, M; Pascual Lledó, JF; Perera López, L	1
Hooten, WM; Warner, DO	1
Borland, R; Brady, K; Carpenter, MJ; Cummings, KM; Fong, GT; Hartwell, K; Hyland, A; Kasza, KA; McKee, SA; Smith, PH	1
Fazel, S; Gumpert, CH; Lichtenstein, P; Molero, Y; Zetterqvist, J	1
Rankin, KV	1
Frey, JM; Gur, RC; Jepson, C; Lerman, C; Loughead, J; Patterson, F; Perkins, KA; Siegel, S; Strasser, AA	1
Spirling, LI; Stapleton, JA; Sutherland, G	1
Cahill, K; Lancaster, T; Stead, L	1
Ferguson, SG; Gritz, ER; Henningfield, JE; Shiffman, S	1
Arteaga, C; Hajek, P; Russ, C; Tonstad, S; Tønnesen, P	1
Noda, K; Saku, K; Tsukahara, H	1
May, AC; Rose, D	1
Ioannides-Demos, LL; McNeil, JJ; Piccenna, L	1
Arteaga, C; Brandon, TH; Gonzales, D; Jorenby, DE; Lee, TC	1
Blendy, JA; Castellano, LM; Turner, JR	1
Cahill, K; Lancaster, T; Stead, LF	3
Childress, AR; Cruz, J; Detre, JA; Franklin, T; Goldman, M; Hazan, R; Li, Y; O'Brien, CP; Suh, JJ; Wang, Z	1
Díaz Cerezo, S; Martí Sánchez, B; Navarro Artieda, R; Sanz De Burgoa, V; Sicras Mainar, A	1
Gur, RC; Lerman, C; Loughead, J; O'Donnell, GP; Ray, R; Ruparel, K; Senecal, N; Siegel, S; Wileyto, EP	1
Dhanji, AR; Hajek, P; McRobbie, HJ; Myers, KE; Stapleton, J	1
Simon, JA	1
Carson, JL; Greenhaus, S; Randall, J; Richardson, DL; Schmelzer, AC; Steinberg, MB	1
Dhelaria, RK; Rothberg, M	1
Ashare, RL; Cummings, KM; Gass, JC; Hawk, LW; Lohnes, SF; Mahoney, MC; Rhodes, JD; Schlienz, NJ; Tiffany, ST	1
Ammerman, S; Bailey, SR; Crew, EE; Killen, JD; Riske, EC; Robinson, TN	1
Ashare, RL; Blair, IA; Leone, F; Mesaros, AC; Strasser, AA; Tang, KZ	1
Ahmad, T; Bishop, SF; De Jaeger, X; Laviolette, SR; Lyons, D; Ng, GA	1
Mikkelsen, K; Tønnesen, P	1
Brown, VL; Cinciripini, PM; Cui, Y; Dani, JA; Engelmann, JM; Karam-Hage, M; Kosten, TR; Lam, CY; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW	1
Carroll, AJ; Hong, LE; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT	1
Abe, TO; Issa, JS; Moura, S; Pereira, AC; Santos, PC	1
Bernabé Barrios, MJ; Rodríguez Hermosa, JL; Santamaría Rodríguez, B; Zamarro García, C	1
Gasparini, F; Kenny, PJ; Markou, A	1
Kratzer, U; Schmidt, WJ	1
Cory-Slechta, DA; Reeves, R; Thiruchelvam, M	1
Wang, HL; Wang, HS; Wu, WR; Xiang, XH; Zhao, Y	1
Baker, CL; Bushmakin, AG; Cappelleri, JC; Gilbert, DG; Merikle, E; Olufade, AO	1
Cao, DY; Guo, Y; Wang, HL; Wang, HS; Wu, WR; Xiang, XH; Zhao, Y	1
Fujii, S; Jia, Y; Sumikawa, K; Yamazaki, Y	1
Frishman, WH	1
Chappell, A; Diaz, MR; DuBois, DW; Läck, AK; McCool, BA	1
Milbrandt, A; Ratcliffe, M; Smith, R; Spirling, LI; Stapleton, JA; Sutherland, G; Watson, L	1
Baker, CL; Bushmakin, AG; Cappelleri, JC; West, R	1
Aubin, HJ; Billing, CB; Bobak, A; Britton, JR; Gong, J; Oncken, C; Reeves, KR; Williams, KE	1
Stapleton, JA	1
Calvo, P; Fernández-López, A; Gómez, T; Revilla, V; Soria, C	1
Ellinwood, EH; Joyner, CM; King, GR	1
Steppuhn, KG; Turski, L	1
Cappendijk, SL; de Vries, R; Dzoljic, MR	1
Beani, L; Bianchi, C; Borea, PA; Simonato, M; Varani, K	1
Fartacek, R; Geretsegger, C	1
Hall, SR; Jhamandas, K; Milne, B; Sullivan, ME	1
Forray, MI; Fuentealba, JA; Gysling, K	1
Jansen van't Land, C; van der Laan, JW	1

Reviews

10 review(s) available for quinoxalines and Substance Withdrawal Syndrome

Article	Year
A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug safety, 2009, Volume: 32, Issue:2 Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Recurrence; Risk Assessment; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline	2009
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacology & therapeutics, 2009, Volume: 123, Issue:1 Topics: Animals; Benzazepines; Bupropion; Clinical Trials as Topic; Humans; Nicotine; Quinoxalines; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2009
Smoking cessation-recent advances. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Humans; Immunotherapy, Active; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Transdermal Patch; Treatment Outcome; United Kingdom; United States; Varenicline	2010
Nicotine receptor partial agonists for smoking cessation. The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12 Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline	2010
Nicotine receptor partial agonists for smoking cessation. The Cochrane database of systematic reviews, 2011, Feb-16, Issue:2 Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline	2011
Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatric drugs, 2012, Apr-01, Volume: 14, Issue:2 Topics: Adolescent; Benzazepines; Bupropion; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Patient Compliance; Prescription Drugs; Quinoxalines; Randomized Controlled Trials as Topic; Safety; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2012
Nicotine receptor partial agonists for smoking cessation. The Cochrane database of systematic reviews, 2012, Apr-18, Issue:4 Topics: Alkaloids; Azepines; Azocines; Benzazepines; Bupropion; Counseling; Heterocyclic Compounds, 4 or More Rings; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline	2012
[Smoking in COPD]. Archivos de bronconeumologia, 2011, Volume: 47 Suppl 8 Topics: Benzazepines; Bupropion; Clonidine; Comorbidity; Disease Progression; Europe; Humans; Motivation; Nicotinic Agonists; Nortriptyline; Prevalence; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Severity of Illness Index; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline	2011
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. Preventive cardiology, 2007,Spring, Volume: 10, Issue:2 Suppl 1 Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline	2007
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology, 2008, Volume: 197, Issue:3 Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Follow-Up Studies; Humans; Middle Aged; Motivation; Multicenter Studies as Topic; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline	2008

Trials

18 trial(s) available for quinoxalines and Substance Withdrawal Syndrome

Article	Year
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA psychiatry, 2013, Volume: 70, Issue:5 Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Delayed-Action Preparations; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult	2013
Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013, Volume: 15, Issue:11 Topics: Adult; Aged; Benzazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Varenicline	2013
Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC medicine, 2013, May-29, Volume: 11 Topics: Adult; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2013
Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial. Contemporary clinical trials, 2014, Volume: 38, Issue:2 Topics: Adult; Benzazepines; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Research Design; Smoking Cessation; Socioeconomic Factors; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Varenicline	2014
Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Addictive behaviors, 2015, Volume: 42 Topics: Adult; Analgesics, Opioid; Benzazepines; Chronic Pain; Depression; Feasibility Studies; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Opioid-Related Disorders; Pain Measurement; Pilot Projects; Quinoxalines; Single-Blind Method; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline	2015
Varenicline improves mood and cognition during smoking abstinence. Biological psychiatry, 2009, Jan-15, Volume: 65, Issue:2 Topics: Adult; Affect; Attention; Benzazepines; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Memory, Short-Term; Middle Aged; Nicotinic Agonists; Quinoxalines; Reaction Time; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline	2009
Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction (Abingdon, England), 2009, Volume: 104, Issue:9 Topics: Benzazepines; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Varenicline	2009
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:4 Topics: Administration, Cutaneous; Adult; Benzazepines; Emotions; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking; Smoking Cessation; Stress, Psychological; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline	2010
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. Addiction (Abingdon, England), 2010, Volume: 105, Issue:11 Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Labeling; Female; Health Knowledge, Attitudes, Practice; Humans; Logistic Models; Male; Middle Aged; Motivation; Nicotinic Agonists; Placebos; Quinoxalines; Secondary Prevention; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Varenicline; Young Adult	2010
Effects of varenicline on smoking cue–triggered neural and craving responses. Archives of general psychiatry, 2011, Volume: 68, Issue:5 Topics: Adult; Basal Ganglia; Benzazepines; Conditioning, Psychological; Cues; Dose-Response Relationship, Drug; Double-Blind Method; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Male; Motivation; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline	2011
Brain activity and emotional processing in smokers treated with varenicline. Addiction biology, 2013, Volume: 18, Issue:4 Topics: Adolescent; Adult; Affect; Aged; Amygdala; Analysis of Variance; Benzazepines; Brain; Cross-Over Studies; Double-Blind Method; Emotions; Facial Expression; Female; Functional Neuroimaging; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Nicotinic Agonists; Oxygen; Photic Stimulation; Placebos; Quinoxalines; Reaction Time; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult	2013
Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Archives of internal medicine, 2011, Apr-25, Volume: 171, Issue:8 Topics: Adult; Benzazepines; Biomarkers; Cotinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; London; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Varenicline	2011
Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Addictive behaviors, 2011, Volume: 36, Issue:12 Topics: Adult; Aged; Behavior Therapy; Benzazepines; Counseling; Double-Blind Method; Feasibility Studies; Female; Hospitalization; Humans; Male; Middle Aged; Motivation; Nicotinic Agonists; Pilot Projects; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult	2011
The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:2 Topics: Behavior, Addictive; Benzazepines; Female; Humans; Male; Medication Adherence; Middle Aged; Nicotinic Agonists; Quinoxalines; Sex Characteristics; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Tobacco Use Disorder; Varenicline	2012
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:10 Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Behavior, Addictive; Benzazepines; Biomarkers; Cotinine; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Pennsylvania; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Varenicline; Young Adult	2012
Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013, Volume: 15, Issue:2 Topics: Benzazepines; Body Weight; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Antagonists; Placebos; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Varenicline	2013
Individual differences in amygdala reactivity following nicotinic receptor stimulation in abstinent smokers. NeuroImage, 2013, Feb-01, Volume: 66 Topics: Adult; Amygdala; Benzazepines; Brain Mapping; Cross-Over Studies; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Varenicline; Young Adult	2013
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax, 2008, Volume: 63, Issue:8 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Benzazepines; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Patient Compliance; Quinoxalines; Reinforcement, Psychology; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline	2008

Other Studies

39 other study(ies) available for quinoxalines and Substance Withdrawal Syndrome

Article	Year
Abstinence Rate, Adverse Events and Withdrawal Symptoms after Varenicline Use and Predicting Factors of Smoking Abstinence: A Multicentre Single-State Study in Malaysia. International journal of environmental research and public health, 2022, 06-24, Volume: 19, Issue:13 Topics: Adolescent; Adult; Benzazepines; Bupropion; Cohort Studies; Humans; Malaysia; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline	2022
Rescue of glutamate transport in the lateral habenula alleviates depression- and anxiety-like behaviors in ethanol-withdrawn rats. Neuropharmacology, 2018, Volume: 129 Topics: Alcoholism; Amino Acid Transport System X-AG; Animals; Antidepressive Agents; Anxiety; Ceftriaxone; Central Nervous System Depressants; Depression; Ethanol; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Habenula; In Vitro Techniques; Kainic Acid; Male; Maze Learning; Nerve Tissue Proteins; Quinoxalines; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Substance Withdrawal Syndrome; Swimming; Tetrodotoxin	2018
Alcohol withdrawal drives depressive behaviors by activating neurons in the rostromedial tegmental nucleus. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019, Volume: 44, Issue:8 Topics: 2-Amino-5-phosphonovalerate; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Clozapine; Dopaminergic Neurons; Ethanol; gamma-Aminobutyric Acid; Male; Microinjections; Neural Inhibition; Neural Pathways; Nucleus Accumbens; Proto-Oncogene Proteins c-fos; Quinoxalines; Quinpirole; Rats; Substance Withdrawal Syndrome; Tegmentum Mesencephali; Ventral Tegmental Area	2019
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:10 Topics: Animals; Anxiety; Azetidines; Benzazepines; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Partial Agonism; Evoked Potentials; Hippocampus; Male; Mice; Microinjections; Motor Activity; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Up-Regulation; Varenicline	2013
Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:2 Topics: Alkaloids; Animals; Azocines; Benzazepines; Infusion Pumps, Implantable; Male; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Varenicline	2014
Varenicline may reduce negative effect while aiding smoking cessation. Evidence-based medicine, 2014, Volume: 19, Issue:1 Topics: Benzazepines; Bupropion; Counseling; Depression; Female; Humans; Male; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome	2014
Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. Journal of neurochemistry, 2014, Volume: 129, Issue:4 Topics: Animals; Anti-Anxiety Agents; Anxiety; Azetidines; Benzazepines; Brain Chemistry; Drug Evaluation, Preclinical; Feeding Behavior; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Cessation; Tobacco Use Disorder; Up-Regulation; Varenicline; Weight Gain	2014
Searching for phenotypes in smoking cessation treatment. International journal of clinical practice, 2014, Volume: 68, Issue:12 Topics: Adult; Aged; Behavior Therapy; Benzazepines; Bupropion; Effect Modifier, Epidemiologic; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Phenotype; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome	2014
Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2015, Volume: 17, Issue:4 Topics: Adolescent; Adult; Australia; Benzazepines; Canada; Female; Gender Identity; Humans; Longitudinal Studies; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; United Kingdom; United States; Varenicline	2015
Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ (Clinical research ed.), 2015, Jun-02, Volume: 350 Topics: Accidents, Traffic; Adolescent; Adult; Aged; Benzazepines; Cohort Studies; Crime; Epidemiologic Methods; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Suicide; Tobacco Use Cessation Devices; Varenicline; Young Adult	2015
New kid on the block: Chantix for smoking cessation. Texas dental journal, 2008, Volume: 125, Issue:5 Topics: Administration, Oral; Benzazepines; Drug Administration Schedule; Drug Approval; Humans; Nausea; Quinoxalines; Receptors, Cholinergic; Receptors, Nicotinic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tablets; Varenicline	2008
Suicidal ideation and varenicline: a possible case of mistaken adverse drug reaction? The Journal of clinical psychiatry, 2008, Volume: 69, Issue:11 Topics: Adult; Benzazepines; Humans; Male; Quinoxalines; Self-Injurious Behavior; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Suicide; Suicide Prevention; Varenicline	2008
Varenicline withdrawal-induced delirium with psychosis. The American journal of psychiatry, 2010, Volume: 167, Issue:6 Topics: Adult; Benzazepines; Delirium; Female; Humans; Nicotinic Agonists; Psychotic Disorders; Quinoxalines; Substance Withdrawal Syndrome; Varenicline	2010
Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2011, Volume: 13, Issue:1 Topics: Animals; Benzazepines; Cerebral Cortex; Hippocampus; Male; Mice; Nicotine; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Thalamus; Up-Regulation; Varenicline	2011
[Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care]. Atencion primaria, 2011, Volume: 43, Issue:9 Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Longitudinal Studies; Male; Middle Aged; Nicotine; Nicotinic Agonists; Primary Health Care; Quinoxalines; Retrospective Studies; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline; Young Adult	2011
Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking". Archives of internal medicine, 2011, Apr-25, Volume: 171, Issue:8 Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Nasal Sprays; Nebulizers and Vaporizers; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Transdermal Patch; Treatment Outcome; Varenicline	2011
Is varenicline effectiveness declining in randomized trials? Archives of internal medicine, 2011, Oct-24, Volume: 171, Issue:19 Topics: Benzazepines; Female; Humans; Male; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome	2011
The effects of AMPA receptor blockade in the prelimbic cortex on systemic and ventral tegmental area opiate reward sensitivity. Psychopharmacology, 2013, Volume: 225, Issue:3 Topics: Analgesics, Opioid; Animals; Conditioning, Psychological; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Male; Microinjections; Morphine; Prefrontal Cortex; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Reward; Substance Withdrawal Syndrome; Ventral Tegmental Area	2013
Alpha oscillations in response to affective and cigarette-related stimuli in smokers. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013, Volume: 15, Issue:5 Topics: Adult; Attention; Benzazepines; Brain; Bupropion; Cues; Demography; Electroencephalography Phase Synchronization; Emotions; Female; Humans; Male; Middle Aged; Motivation; Nicotinic Agonists; Photic Stimulation; Quinoxalines; Recurrence; Self Report; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Tobacco Products; Varenicline	2013
Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013, Volume: 15, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Benzazepines; Brazil; Bupropion; Demography; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline	2013
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:3 Topics: Animals; Bridged Bicyclo Compounds; Dizocilpine Maleate; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Male; Nicotine; Pyridines; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Reward; Substance Withdrawal Syndrome; Ventral Tegmental Area	2003
Caroverine inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neuroscience letters, 2003, Oct-02, Volume: 349, Issue:2 Topics: Analgesics, Opioid; Animals; Avoidance Learning; Conditioning, Classical; Male; Morphine; Naloxone; Narcotic Antagonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2003
Development of behavioral sensitization to the cocaine-like fungicide triadimefon is prevented by AMPA, NMDa, DA D1 but not DA D2 receptor antagonists. Toxicological sciences : an official journal of the Society of Toxicology, 2004, Volume: 79, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Benzazepines; Brain Chemistry; Corpus Striatum; Drug Administration Schedule; Fungicides, Industrial; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Neuronal Plasticity; Piperazines; Quinoxalines; Receptors, AMPA; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Remoxipride; Substance Withdrawal Syndrome; Time Factors; Triazoles	2004
Blockade of ionotropic glutamatergic transmission in the ventral tegmental area attenuates the physical signs of morphine withdrawal in rats. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:7 Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Microinjections; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Substance Withdrawal Syndrome; Synaptic Transmission; Ventral Tegmental Area; Weight Loss	2004
Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. Current medical research and opinion, 2005, Volume: 21, Issue:5 Topics: Adolescent; Adult; Aged; Benzazepines; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Minnesota; Nicotinic Agonists; Psychometrics; Quinoxalines; Reproducibility of Results; Severity of Illness Index; Sickness Impact Profile; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tobacco Use Disorder; Varenicline	2005
Ionotropic glutamatergic neurotransmission in the ventral tegmental area modulates DeltaFosB expression in the nucleus accumbens and abstinence syndrome in morphine withdrawal rats. European journal of pharmacology, 2005, Dec-19, Volume: 527, Issue:1-3 Topics: Animals; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Immunohistochemistry; Male; Microinjections; Morphine; Morphine Dependence; Naloxone; Nucleus Accumbens; Protein Isoforms; Proto-Oncogene Proteins c-fos; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Synaptic Transmission; Ventral Tegmental Area	2005
Nicotine withdrawal suppresses nicotinic modulation of long-term potentiation induction in the hippocampal CA1 region. The European journal of neuroscience, 2006, Volume: 24, Issue:10 Topics: Animals; Azetidines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Female; GABA Antagonists; Hippocampus; Inhibitory Postsynaptic Potentials; Long-Term Potentiation; Male; Nicotine; Nicotinic Agonists; Picrotoxin; Quinoxalines; Rats; Substance Withdrawal Syndrome; Time Factors; Up-Regulation	2006
Chronic ethanol and withdrawal differentially modulate pre- and postsynaptic function at glutamatergic synapses in rat basolateral amygdala. Journal of neurophysiology, 2007, Volume: 98, Issue:6 Topics: Administration, Inhalation; Amygdala; Animals; Anxiety; Central Nervous System Depressants; Data Interpretation, Statistical; Electrophysiology; Ethanol; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Glutamates; Male; Microinjections; Neurotransmitter Agents; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Synapses; Synaptic Transmission; Tetrodotoxin	2007
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction (Abingdon, England), 2008, Volume: 103, Issue:1 Topics: Adult; Benzazepines; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; London; Male; Mental Disorders; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline	2008
Breaking away from a narrow prescribing protocol for medicinal nicotine. Addiction (Abingdon, England), 2008, Volume: 103, Issue:4 Topics: Administration, Cutaneous; Adult; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline	2008
Effect of morphine and abstinence syndrome on [3H]bromoxidine binding to alpha 2-adrenoceptors in rat brain. Neurochemical research, 1994, Volume: 19, Issue:4 Topics: Adrenergic alpha-Agonists; Animals; Autoradiography; Brain; Brimonidine Tartrate; Drug Implants; Hippocampus; Male; Mesencephalon; Morphine; Morphine Dependence; Naloxone; Occipital Lobe; Organ Specificity; Quinoxalines; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2; Reference Values; Substance Withdrawal Syndrome; Superior Colliculi; Tritium	1994
Withdrawal from continuous or intermittent cocaine: behavioral responsivity to 5-HT1 receptor agonists. Pharmacology, biochemistry, and behavior, 1993, Volume: 45, Issue:3 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Cocaine; Drug Tolerance; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Receptor Agonists; Substance Withdrawal Syndrome	1993
Diazepam dependence prevented by glutamate antagonists. Proceedings of the National Academy of Sciences of the United States of America, 1993, Jul-15, Volume: 90, Issue:14 Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Diazepam; Drug Tolerance; Electroencephalography; Electromyography; Excitatory Amino Acid Antagonists; Male; Mice; Mice, Inbred Strains; Motor Activity; Muscle Tonus; Piperazines; Quinoxalines; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors	1993
Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1993, Volume: 3, Issue:2 Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Glycine; Kynurenic Acid; Male; Mice; Morphine Dependence; Naloxone; Quinoxalines; Receptors, Amino Acid; Receptors, Glycine; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Substance Withdrawal Syndrome	1993
Changes in [3H]-UK 14304 binding to alpha 2-adrenoceptors in morphine-dependent guinea-pigs. British journal of pharmacology, 1995, Volume: 116, Issue:8 Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cerebral Cortex; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Guinea Pigs; In Vitro Techniques; Male; Morphine Dependence; Naloxone; Narcotic Antagonists; Norepinephrine; Quinoxalines; Receptors, Adrenergic, alpha-2; Substance Withdrawal Syndrome; Synaptosomes; Tritium	1995
Infusional high-dose application of the calcium-channel-blocking and antiglutamatergic agent caroverine in the treatment of alcohol withdrawal (DSM-III-R 291.80). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1998, Volume: 8, Issue:3 Topics: Adult; Alcohols; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Calcium Channel Blockers; Excitatory Amino Acid Antagonists; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; N-Methylaspartate; Pilot Projects; Quinoxalines; Substance Withdrawal Syndrome	1998
Suppression of acute and chronic opioid withdrawal by a selective soluble guanylyl cyclase inhibitor. Brain research, 2000, Mar-17, Volume: 859, Issue:1 Topics: Analgesics, Opioid; Animals; Behavior, Animal; Cyclic GMP; Enzyme Inhibitors; Excitatory Amino Acids; Guanylate Cyclase; Locus Coeruleus; Male; Morphine; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2000
Chronic morphine treatment and withdrawal increase extracellular levels of norepinephrine in the rat bed nucleus of the stria terminalis. Journal of neurochemistry, 2000, Volume: 75, Issue:2 Topics: Adrenergic alpha-Agonists; Animals; Brain; Brimonidine Tartrate; Extracellular Space; Glutamic Acid; In Vitro Techniques; Male; Microdialysis; Morphine; Morphine Dependence; Norepinephrine; Quinoxalines; Rats; Rats, Sprague-Dawley; Septal Nuclei; Substance Withdrawal Syndrome	2000
Chronic infusion of clonidine does not alleviate spontaneous morphine withdrawal symptoms in rats. Psychopharmacology, 1992, Volume: 108, Issue:3 Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Clonidine; Doxazosin; Drug Implants; Eating; Food; Male; Morphine; Morphine Dependence; Motor Activity; Prazosin; Quinoxalines; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome	1992